Peptide Companion
Back to catalog
Peptide Companion
single
Growth Hormone
Vial: 5 mg

CJC-1295 NO DAC (5 mg Vial)

CJC-1295 NO DAC dosage protocols leverage this synthetic 29‑amino‑acid GHRH analog (also known as Modified GRF 1–29 or Mod GRF) to stimulate natural, pulsatile growth hormone secretion from the pituitary gland. Unlike exogenous GH administration, CJC-1295 NO DAC preserves the body’s physiologic feedback loop, supporting enhanced GH and IGF‑1 levels while maintaining natural hormonal rhythms. Research suggests benefits may include improved body composition, enhanced recovery, better sleep quality, and support for lean muscle mass and metabolic function. This educational protocol presents a practical once‑daily subcutaneous approach using a dilution optimized for clear insulin‑syringe measurements.

Dose
0.1–0.2 mg per injection
Frequency
2–3 times daily
Timing
Morning, post-workout, before bed
Duration
8–12 weeks

Short-acting version. Mimics natural GH pulses. Best combined with GHRP peptides.

Dosing Schedule
WeekDaily Dose (mcg)Units (per injection) (mL)
Weeks 1–2100 mcg6 units (0.06 mL)
Weeks 3–4150 mcg9 units (0.09 mL)
Weeks 5–6200 mcg12 units (0.12 mL)
Weeks 7–12250–300 mcg15–18 units (0.15–0.18 mL)
Supplies Needed
  • •Peptide Vials (CJC-1295 NO DAC, 5 mg each):
  • •Insulin Syringes (U‑100):
  • •Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
References

  • Wikipedia

    Modified GRF (1–29): structure, amino acid substitutions, and pharmacokinetics

    View source

  • Journal of Clinical Endocrinology & Metabolism (2006)

    Teichman et al.: Prolonged stimulation of GH and IGF‑I by CJC-1295 in healthy adults

    View source

  • American Journal of Physiology (2006)

    Alba et al.: Once‑daily CJC-1295 normalizes growth in GHRH knockout mice

    View source

  • Journal of Clinical Endocrinology & Metabolism (2006)

    Veldhuis et al.: Pulsatile GH secretion persists during continuous CJC-1295 stimulation

    View source

  • PMC

    Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF‑1 Levels

    View source

  • PMC

    Effects of GHRH Analog (Tesamorelin) on Endogenous GH Pulsatility and Insulin Sensitivity

    View source

  • PMC

    Sermorelin: a better approach to management of adult‑onset growth hormone insufficiency

    View source

  • PMC

    Beyond the androgen receptor: role of GHS in body composition in hypogonadal males

    View source

  • PMC

    The Safety and Efficacy of Growth Hormone Secretagogues (Review)

    View source

  • PMC

    GHRH Effects on Brain GABA Levels in Mild Cognitive Impairment and Healthy Aging

    View source

  • PubMed

    Sermorelin: review of its use in diagnosis and treatment of GH deficiency

    View source

  • CDC

    Vaccine administration: subcutaneous route (angle/site; no aspiration)

    View source

  • CDC (Subcut Injection PDF)

    Technique diagram and site guidance for subcutaneous injections

    View source

  • NCBI Bookshelf

    Best practices for injection (asepsis, preparation, and administration)

    View source

  • Subcutaneous Drug Injection Review (PMC)

    Pharmacologic considerations of the subcutaneous route

    View source

Educational content adapted from peptidedosages.com. Not medical advice.